Searched for
SAMSUNG BIOLOGICS
Kospi jumps over 8% on Iran peace deal hopes; world's best-performing market up 94% YTDSouth Korean stocks surged on Friday, with the KOSPI jumping as much as 8.5%, driven by optimism that Middle East tensions could ease after...- South Korean shares hit record high on export surge, Nvidia optimismSouth Korean stocks surged to record highs on Monday. Strong chip exports fueled the rally, boosted by hopes of AI collaborations with Nvid...
- Samsung’s $416,000 chip worker bonuses may reshape labour battles in South KoreaSamsung Electronics has agreed to a significant bonus deal with its union, a move that could reshape wage bargaining in South Korea. Memory...
- South Korean shares end 8% higher as Samsung hits record on pay dealSouth Korean shares surged 8% on Thursday, led by Samsung Electronics reaching a record high after a labor deal averted a strike, easing ec...
- Global Markets | South Korean shares dip, but mark second weekly gain on Iran ceasefire hopesSouth Korean stocks ended lower Friday but secured a second weekly gain. Hopes for a U.S.-Iran ceasefire boosted sentiment. The Korean won ...
- Global Markets | S.Korean shares log highest close since Feb on hopes of US-Iran talksSouth Korean shares climbed to their highest close since February as optimism over renewed US-Iran talks boosted global risk sentiment and ...
- With sights on huge gains, Biocon to scale up AI focusBiopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing...
- South Korean shares fall 3%, won hits 17-year low on Mideast worriesSouth Korean financial markets experienced a significant downturn on Monday. The main stock index, KOSPI, dropped by almost 3%. The nationa...
- Samsung Biologics to buy US drug production facility from GSK for $280 millionSamsung Biologics is acquiring its first U.S. drug production facility from GSK for $280 million to meet long-term U.S. market demand. The ...
- Samsung, SK Hynix shares leap after OpenAI chip dealSouth Korean shares soared to a record high on Thursday, driven by a significant surge in chipmakers Samsung Electronics and SK Hynix. Both...
- Experts speculate Samsung's spinoff of foundry business will boost trust and competitiveness, Samsung says it's too earlySamsung may separate its foundry business from its semiconductor division. This move addresses conflict of interest concerns. It mirrors a ...
- Seoul appeals court finds Samsung chief Lee not guilty in merger caseSamsung Electronics Chairman Jay Y. Lee was found not guilty of accounting fraud and stock manipulation by a Seoul appeals court on Monday,...
- Dr Reddy's Laboratories jumps into the fray for Biogen's biosimilarsDr Reddy's Laboratories (DRL) and Intas Pharmaceuticals, both Indian companies, are reportedly in the race to acquire the biosimilar produc...
- Samsung Biologics unveils $897 mln manufacturing deals for PfizerSouth Korea's Samsung Biologics announced on Tuesday two deals with Pfizer worth a combined $897 million to manufacture products for the U....
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Samsung's Lee visits US ahead of likely $17 billion chip plant decisionSamsung Electronics vice chairman Jay Y. Lee left Seoul on Sunday and his trip to Canada and the United States is expected to coincide with...
- Samsung heir charged with fraud over 2015 mergerLee, who has already served jail time in connection with a separate case, and 10 other current and former Samsung executives were indicted ...
- Sun Pharma gains on signing deal with Samsung BioLogicsFollowing the development, the stock gained 0.24 per cent to Rs 550.65 on BSE.
- Sun Pharmaceutical signs agreement with Samsung BioLogics for psoriasis drugThe novel drug known as Tildrakizumab is currently under review by the US FDA and the European Medicines Agency (EMA). The value of the con...
- Sun Pharma inks $55.5-mn deal for anti-psoriasis drugSun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.
Load More
